Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Palladium-103 brachytherapy for prostate carcinoma.

Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W.

Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):839-50.

PMID:
10705004
2.

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy.

Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):31-40.

PMID:
11516848
3.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
4.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
5.

Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy.

Lederman GS, Cavanagh W, Albert PS, Israeli R, Lessing J, Savino M, Volpicella F.

Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1297-303.

PMID:
11286837
6.

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience.

Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):944-52.

PMID:
14575824
7.
8.

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.

Merrick GS, Butler WM, Galbreath RW, Lief JH.

Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):41-8.

PMID:
11516849
10.

Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses.

Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):282-9.

PMID:
12023131
11.

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.

Ellis RJ, Vertocnik A, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ.

Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):362-70.

PMID:
12957246
12.

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.

Dattoli M, Wallner K, Sorace R, Koval J, Cash J, Acosta R, Brown C, Etheridge J, Binder M, Brunelle R, Kirwan N, Sanchez S, Stein D, Wasserman S.

Int J Radiat Oncol Biol Phys. 1996 Jul 15;35(5):875-9.

PMID:
8751395
13.
14.

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8.

PMID:
21985944
15.

20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.

Wallner K, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W.

Radiother Oncol. 2005 Jun;75(3):307-10.

PMID:
16086912
16.
17.

A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.

Potters L, Cao Y, Calugaru E, Torre T, Fearn P, Wang XH.

Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):605-14.

PMID:
11395226
18.

125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.

Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1297-303.

PMID:
14630265
20.

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):32-43.

PMID:
15629591

Supplemental Content

Support Center